M&A Deal Summary |
|
|---|---|
| Date | 2010-12-10 |
| Target | OPKO - Rolapitant |
| Sector | Life Science |
| Buyer(s) | Tesaro |
| Sellers(s) | Opko |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2010 |
| Sector | Life Science |
| Employees | 275 |
| Revenue | 223M USD (2017) |
Tesaro, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of patients with cancer. Tesaro develops and will commercialize safer and more effective supportive care agents and therapeutics. Tesaro, Inc. was founded in 2010 and is based in Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2010 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1991 |
| Sector | Life Science |
| Employees | 2,997 |
| Revenue | 713M USD (2024) |
Opko is a diversified healthcare company with a focus on establishing leading positions in significant and rapidly growing medical markets. Opko's operations are divided into diagnostics and pharmaceuticals, each with specialized products and services aimed at improving patient care and outcomes. Opko was founded in 1991 and is based in Miami, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Divestiture M&A Deals | 1 of 3 |
| Country: United States M&A | 1 of 2 |
| Year: 2010 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-02-18 |
Pharmacos Exakta S.A. de C.V.
Guadalajara, Mexico Pharmacos Exakta, S.A. de C.V. is a privately-owned Mexican pharmaceutical company engaged in the manufacture, marketing and distribution of ophthalmic and other pharmaceutical products for government and private markets. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-01 |
Curna
Jupiter, Florida, United States Curna, Inc. is a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies. |
Buy | - |
